The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?

Expert Review of Anticancer Therapy

Volumn 12, Issue 5, 2012, Pages 547-549

  Bellail, Anita C ^a   Hao, Chunhai ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; cancer; death receptor; monoclonal antibody; target agents; TRAIL

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DROZITUMAB; DULANERMIN; LEXATUMUMAB; MAPATUMUMAB; PACLITAXEL; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TIGATUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; ADVANCED CANCER; AMINO TERMINAL SEQUENCE; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; COLORECTAL CANCER; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOSURVEILLANCE; IN VITRO STUDY; LIVER CELL; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NATURAL KILLER CELL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84861303356     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.33     Document Type: Review

References (20)

1. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 281(5381), 1305-1308 (1998).
2. Cha SS, Kim MS, Choi YH et al. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 11(2), 253-261 (1999).
3. Ashkenazi A, Pai RC, Fong S et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104(2), 155-162 (1999).
4. Walczak H, Miller RE, Ariail K et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5(2), 157-163 (1999).
5. Jo M, Kim TH, Seol DW et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6(5), 564-567 (2000).
6. Nagata S. Steering anti-cancer drugs away from the TRAIL. Nat. Med. 6(5), 502-503 (2000).
7. Lawrence D, Shahrokh Z, Marsters S et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7(4), 383-385 (2001).
8. Hao C, Song JH, Hsi B et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 64(23), 8502-8506 (2004).
9. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, Van Den Brink MR, Yagita H. Nature's TRAIL - on a path to cancer immunotherapy. Immunity 18(1), 1-6 (2003).
10. Herbst RS, Eckhardt SG, Kurzrock R et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol. 28(17), 2839-2846 (2010).
11. Soria JC, Smit E, Khayat D et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J. Clin. Oncol. 28(9), 1527-1533 (2010).
12. Soria JC, Mark Z, Zatloukal P et al. Randomized Phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J. Clin. Oncol. 29(33), 4442-4451 (2011).
13. Ichikawa K, Liu W, Zhao L et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7(8), 954-960 (2001).
14. Tolcher AW, Mita M, Meropol NJ et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 25(11), 1390-1395 (2007).
15. Plummer R, Attard G, Pacey S et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 13(20), 6187-6194 (2007).
16. Camidge DR, Herbst RS, Gordon MS et al. A Phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin. Cancer Res. 16(4), 1256-1263 (2010).
17. Trarbach T, Moehler M, Heinemann V et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br. J. Cancer 102(3), 506-512 (2010).
18. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials 4(1), 34-41 (2009).
19. Wuchter C, Krappmann D, Cai Z et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia 15(6), 921-928 (2001).
20. Bellail AC, Olson JJ, Yang X, Chen ZJ, Hao C. A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov. 2(2), 140-155 (2012).